What is MGNX (MGNX) stock price today?

MGNX (MGNX) is currently trading at $4.04, up 1.25% today.

What is MGNX P/E ratio?

MGNX's P/E ratio is -2.92. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MGNX return on equity (ROE)?

MGNX's return on equity (ROE) is -140.27%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is MGNX's market cap?

MGNX has a market capitalization of $256.79M.

NASDAQ · Biotechnology

MGNX (MGNX) Stock

$4.04 +1.25% NASDAQ: MGNX Healthcare

Valuation

Metric	Value
Price	$4.04
Market Cap	$256.79M
P/E Ratio	-2.92
P/B Ratio	12.35
P/S Ratio	1.67
EPS (TTM)	$-1.33
52-Week High	$5.03
52-Week Low	$1.19
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-140.27%
ROA	-17.98%
ROCE	-130.36%
Gross Margin	69.93%
Operating Margin	-40.53%
Net Margin	-44.79%
Debt/Equity	1.72
Current Ratio	5.12

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$76.0M	$150.0M	$57.0M	$148.0M	$150.0M
Operating Profit	$-203.0M	$-121.0M	$-168.0M	$-111.0M	$-73.0M
Net Profit	$-202.0M	$-120.0M	$-9.0M	$-67.0M	$-75.0M
EPS	$-3.18	$-1.95	$-0.15	$-1.07	$-1.18
Op Margin	-268.1%	-80.9%	-294.2%	-74.5%	-48.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$335.0M	$290.0M	$298.0M	$262.0M	$257.0M
Total Liabilities	$96.0M	$147.0M	$146.0M	$146.0M	$201.0M
Cash	$123.0M	$109.0M	$101.0M	$183.0M	$57.0M
Borrowings	$25.0M	$35.0M	$34.0M	$37.0M	$107.0M

Latest News

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy Insider Monkey · Jul 5, 2026 VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals MT Newswires · Jul 2, 2026 MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? Zacks · Jul 2, 2026 Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations ACCESS Newswire · Jul 2, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-144.0M	$-87.0M	$-78.0M	$-68.0M	$-81.0M
Investing Cash Flow	$-43.0M	$67.0M	$-82.0M	$146.0M	$-116.0M
Financing Cash Flow	$5.0M	$1.0M	$149.0M	$1.0M	$69.0M
Net Cash Flow	$-58.0M	$-15.0M	$-8.0M	$82.0M	$-126.0M
Free Cash Flow	$-150.0M	$-91.0M	$-80.0M	$-72.0M	$-83.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-2.37
FCF Yield	-27.32%
Quick Ratio	1.80
Interest Coverage	-8.11
Return 1Y	121.55%
Return 3Y	-16.98%
Return 5Y	-82.60%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLNN	$4.11	-4.09%	-1.31	$52.45M	0.00%
CNTB	$2.36	+7.27%	-2.31	$148.59M	0.00%
CNTX	$0.36	-6.52%	-6.84	$33.47M	0.00%
COYA	$4.51	-1.10%	-2.62	$105.79M	0.00%
IFRX	$2.16	+1.41%	-4.16	$318.15M	0.00%

About MGNX

MGNX is led by CEO Eric Blasius Risser, publicly traded since 2013.

MGNX stock trades at $4.04 with a market capitalization of $256.79M. The stock is valued at a price-to-earnings (P/E) ratio of -2.92, price-to-book of 12.35, price-to-sales of 1.67. Over the past 52 weeks the stock has ranged between $1.19 and $5.03, and currently trades 19.7% below its 52-week high.

On profitability, MGNX generates a return on equity (ROE) of -140.27%, return on capital employed of -130.36%, an operating margin of -40.53%, a net profit margin of -44.79%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides